Skip to content

Currently, there is one Duchenne-specific drug under investigation.

It works by allowing the protein machinery to read the instructions for making the protein past the stop-codon that occurs too early in the gene. This allows the gene to produce a functional version of the dystrophin protein.

Drug Name
Type of Drug
DMD Mutations Addressed
Current Development Phase
Approval Status
Oral medication taken three times daily
Nonsense mutation
PTC Therapeutics
Phase 2 in <2 years of age
Phase 3 extension studies
Europe and Brazil for ambulatory boys 2yrs and older